Komii) EPISODE 09 Botox: How the Deadliest Substance on Earth Became a Beauty Empire

The Deadliest Beauty Product

There is a substance so lethal that a quantity smaller than a grain of salt could kill a room full of people, having been studied as a biological weapon and remaining the reason your grandmother told you to throw away a dented tin. Every year, millions of people pay to have it injected into their face.

Now, before you jump to the obvious, nobody planned this, and there was no laboratory where somebody decided to turn a poison into a beauty product. It was found by accident in Vancouver in nineteen eighty-seven by a married couple who were treating something completely unrelated, solely because of a single offhand comment from a patient. And here is the part that should stop you cold: nothing was invented, not one new molecule, and not one new compound. The substance already existed, was already approved, and was already being injected into people.

Somebody just noticed what else it did, and the business lesson buried in this is one of the most valuable on this entire channel, having almost nothing to do with beauty.

The Stakes

Since the American cosmetic approval in two thousand and two, an estimated thirteen million vials have been sold in the United States alone. It is the highest-selling product of its kind in the world, and it created an entire industry that did not previously exist, including clinics, training courses, and a whole tier of medicine.

And it did that in a category nobody believed was a category. Before this, cosmetic intervention essentially meant surgery involving anaesthetic, recovery, real risk, a significant sum of money, and a week where you could not be seen. This was fifteen minutes in a chair.

Quick thing before we get into how it happened: most people who watch these all the way through still are not subscribed. If you like knowing where the things around you actually came from, hit subscribe, because this one gets genuinely strange.

The Mechanism

In nineteen eleven, an Austrian economist named Joseph Schumpeter published a theory of economic development and made an argument most people still get completely wrong about innovation: he said innovation is rarely invention, but is almost always recombination—new combinations of things that already exist. A new product from existing materials, an existing product sold to a new market, or an existing process pointed at a new purpose.

Schumpeter's point was that the value does not sit in the discovery, but in the recombining, and the person who does the recombining is very often not the person who made the original thing. Now hold that against what happened here. The toxin had been known for over a century; its paralysing effect was thoroughly documented, and a doctor had already turned it into an approved treatment for an eye condition, meaning every single component existed.

What did not exist was somebody looking at a clinical side effect and seeing a market of hundreds of millions of people.

The Rise

The medical story starts with strabismus, or crossed eyes. The condition is caused by eye muscles pulling unevenly, and the conventional fix was surgery, but in the nineteen seventies an American ophthalmologist named Alan Scott had a different idea: if the problem is a muscle pulling too hard, you do not need to cut anything; you just need that muscle to relax. And there was a substance already known to do exactly that in extremely small quantities.

It took years of testing, and in nineteen eighty-nine, after roughly a decade of that process, a then small company called Allergan acquired it and began selling it to ophthalmologists. At that point, this was a niche eye medicine—useful, unglamorous, and with nobody in that entire chain thinking about faces.

Then came Vancouver, nineteen eighty-seven. Jean Carruthers was an ophthalmologist using the toxin to treat eye muscle conditions, and her husband, Alastair Carruthers, was a dermatologist. A patient who had been receiving the injections for a medical condition mentioned that the lines between her eyebrows had softened and she wanted that part to continue. Jean Carruthers went home and told her husband, and between an eye doctor and a skin doctor at the same dinner table, the two halves of the observation finally met.

The Crack

In nineteen ninety two, the Carruthers published the first medical report proposing cosmetic use. It took another decade of trials and process, but on the fifteenth of April, two thousand and two, American regulators approved it cosmetically for moderate to severe frown lines between the eyebrows. One narrow approval for one small area of the face opened a market that had not previously existed.

Now here is the part that is genuinely fascinating from a business perspective: that approval was extremely specific, supporting only one indication and one region. But once a product is approved and on the market, doctors may use their clinical judgement to prescribe it for other purposes, which is called off-label use—a legal and normal part of medicine. So the product's actual use expanded enormously faster than its approvals did.

Which created a very strange commercial situation: the company could only market what was approved, but the demand was being driven by things it could not advertise at all. So the growth engine was not advertising, but practitioners talking to each other and patients talking to each other.

The Self Inflicted Wound

And that word-of-mouth engine worked so well that it created a trap, which is right there in how you and I have been talking about this entire time. People do not say botulinum toxin or name a competing brand; they say one brand name generically for the entire procedure, regardless of which product is actually being used.

That looks like the ultimate marketing achievement, but it is also a genuine commercial danger that companies spend heavily fighting. When your brand becomes the generic word for a category, several things happen: you lose the ability to differentiate, competing products get sold under the umbrella of your name, and in some jurisdictions, a trademark that becomes fully generic can weaken. Ask an escalator, a thermos, or a trampoline how that worked out, as all three were once brand names.

So the position today is genuinely odd: the category is enormous and still growing, competitor toxins have entered, and the market leader's own name is doing free work for products that are not its own every single time somebody books an appointment. It is not a wound that came from a bad decision, but from winning too completely.

The Exception

And now the part I find genuinely moving, which rarely makes it into videos about this: the cosmetic use funded the medical use. Because of the revenue this generated, the same compound has been developed and approved for a long list of conditions that have nothing whatsoever to do with appearance, such as chronic migraine, cervical dystonia where neck muscles contract involuntarily and painfully, spasticity after stroke, and excessive sweating severe enough to disrupt somebody's working life.

For people with those conditions, this is not a beauty product, but the thing that gave them their week back. And the reason the research existed to develop those uses is substantially the money that came from frown lines. That is the argument for the whole messy system, and it is the strongest version of it: a cosmetic market subsidised a set of treatments that would never have attracted that level of investment on their own.

If you know somebody who dismisses all of this as pure vanity medicine, send them this. Send it to three people, because the thing that gets mocked at parties is the thing paying for migraine research.

The Counter Case

Now consider the serious objections, and there are several. The training standards for who may inject vary enormously between countries, and in some places they are close to nonexistent, posing a real safety issue that is not scaremongering to highlight.

There is a legitimate argument that the normalisation of cosmetic intervention, particularly among very young people and particularly driven by filtered images, has costs that do not appear in any revenue figure. And the off-label expansion I described neutrally is genuinely contested, as it is a mechanism that allows good medicine to reach patients faster than regulators can move, but also a mechanism that allows use to run well ahead of evidence.

I am not going to tell you which of those matters more, but if you are considering any of this, the only advice in this video is to check the credentials of whoever is holding the needle, because that varies far more than the product does.

The Final Verdict

The patents have weakened and competitors have arrived, meaning there are now multiple approved toxins competing on price and on how long the effect lasts. This indicates the category is entering the phase every successful market eventually reaches, where innovation is finished and competition is about distribution and cost.

Take the Schumpeter lesson with you, because it is the genuinely useful part: the people who found this were not inventors, but an eye doctor and a skin doctor who listened to a patient mention something in passing and were curious enough to follow it. An entire global industry exists because somebody paid attention to an offhand comment about eyebrows.

And the toxin itself has not changed, remaining one of the most dangerous substances known to science that will never change. What changed was the dose, the delivery, and the purpose. Nothing was created here—a poison that had existed forever, an approved eye treatment, and one patient's passing remark were put next to each other to build an empire out of the arrangement. That is what innovation actually looks like most of the time: not a flash of genius, but somebody noticing.

So tell me, what have you noticed lately that everyone around you walked straight past? Leave it in the comments, because I read them.

And most of you watching are still not subscribed, so hit that one click.

Because next time we are going after the greatest advertising campaign ever written—a company that convinced the entire planet that two months of your salary was the correct price of love, and invented a tradition your grandparents believed was ancient. That one will genuinely change how you see something in your own house. See you there.